Sort   by:  
 Page size 
MetabolomicsApoptosis-inducing effects of aqueous extract of Eleutherococcus senticosus on non-small cell lung cancer cell proliferation

Non-small cell lung cancer is a malignant tumor with high morbidity and mortality worldwide. Eleutherococcus senticosus can induce apoptosis in non-small cell lung cancer cells, but the mechanism remains unclear. This study aimed to elucidate the role of Eleutherococcus senticosus in inducing apo...

2025-05-12 | MTBLS10545 | MetaboLights
MetabolomicsGut Microbiota Dysbiosis and Hypercholesterolemia Are Associated with Bone Metastasis in Non-Small Cell Lung Cancer
We collected baseline fecal samples from 85 patients with newly diagnosed lung cancer, 51 patients with bone metastasis (M group), and 34 patients without bone metastasis (N group). We conducted metagenomic and metabolomic sequencing to compare the differences in gut microbiota and metabolites betwe...
2026-07-10 | MTBLS15004 | MetaboLights
MetabolomicsCorrelation between gut microbiota and their metabolites and the efficacy of chemotherapy combined with immunotherapy for extensive-stage small cell lung cancer

Gut microbiota has been reported to be associated with the host’s immune system and immunotherapy response, as well as immune-related adverse events (irAEs). Additionally, gut microbial metabolites have various immunomodulatory effects. Our study focused on the differences in gut microbiota and t...

2025-12-23 | MTBLS13557 | MetaboLights
MetabolomicsChanges in L-phenylalanine concentration reflect and predict response to anti-PD-1 treatment combined with chemotherapy in patients with non-small cell lung cancer
Chemotherapy combined with checkpoint blockade antibodies targeting programmed cell death protein (PD-1) has achieved remarkable success in non-small cell lung cancer (NSCLC). However, few patients benefit from long-term treatment. Therefore, biomarkers capable of guiding the optimal therapeutic sel...
2025-06-16 | MTBLS11232 | MetaboLights
MetabolomicsLactobacillus rhamnosus GG (LGG) exhibits inhibitory effects against non-small cell lung cancer (NSCLC) and alleviates the adverse effects associated with gefitinib_Serum metabolomics study in mice

After screening the bacteria both in vivo and in vitro, it was found that a certain candidate strain could significantly inhibit non-small cell lung cancer when combined with the drug gefitinib and alleviate the side effects of gefitinib. Next, the mechanism will be explored through in vivo and i...

2026-09-03 | MTBLS13812 | MetaboLights
MetabolomicsLactobacillus rhamnosus GG (LGG) exhibits inhibitory effects against non-small cell lung cancer (NSCLC) and alleviates the adverse effects associated with gefitinib_Fecal metabolomics study in mice

After screening the bacteria both in vivo and in vitro, it was found that a certain candidate strain could significantly inhibit non-small cell lung cancer when combined with the drug gefitinib and alleviate the side effects of gefitinib. Next, the mechanism will be explored through in vivo and i...

2026-09-03 | MTBLS13811 | MetaboLights
MetabolomicsLactobacillus rhamnosus GG (LGG) exhibits inhibitory effects against non-small cell lung cancer (NSCLC) and alleviates the adverse effects associated with gefitinib_Metabolite study of culture medium supernatant

After screening the bacteria both in vivo and in vitro, it was found that a certain candidate strain could significantly inhibit non-small cell lung cancer when combined with the drug gefitinib and alleviate the side effects of gefitinib. Next, the mechanis...

2026-09-03 | MTBLS13843 | MetaboLights
MetabolomicsSmall cell lung cancer metabolome (part II)
Not available
ORGANISM(S): Homo sapiens 
ST000220 | MetabolomicsWorkbench
MetabolomicsNon-invasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer
Lung cancer remains the most common cause of cancer deaths worldwide, yet there is currently a lack of diagnostic noninvasive biomarkers that could guide treatment decisions. Small molecules (<1500 Da) were measured in urine collected from 469 lung cancer patients and 536 population controls using u...
2014-05-06 | MTBLS28 | MetaboLights
MetabolomicsTargeting GSTZ1 sensitizes KRASG12C-mutant lung cancer cells by overcoming glutathione and glycolysis pathway rewiring

KRAS mutations are prevalent in lung cancer, but KRAS G12C inhibitors exhibit limited efficacy, partly due to metabolic adaptations, such as enhanced glutathione metabolism and increased glycolysis. Glutathione S-Transferase Zeta 1 (GSTZ1) is a metabolic enzyme that regulates cell metabolism. How...

2026-05-15 | MTBLS12791 | MetaboLights
Sort   by:  
 Page size